Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934999 | 0.89 | PTGDR2 (0.60) | MEN1USP2KMT2ATRPM8PTGDR2 | |
| SCHEMBL934148 | 0.80 | PTGDR2 (0.54) | MEN1USP2KMT2APTGDR2LMNA | |
| SCHEMBL934733 | 0.80 | CHRM2 (0.45) | MEN1USP2KMT2ATRPM8PTGDR2 | |
| SCHEMBL934199 | 0.80 | PTGDR2 (0.56) | MEN1USP2KMT2APTGDR2LMNA | |
| SCHEMBL934647 | 0.80 | PTGDR2 (0.46) | MEN1USP2KMT2APTGDR2KCNN4 | |
| SCHEMBL935192 | 0.79 | PTGDR2 (0.57) | MEN1KMT2APTGDR2 | |
| SCHEMBL933849 | 0.79 | PTGDR2 (0.43) | MEN1USP2KMT2APTGDR2KCNN4 | |
| SCHEMBL30582806 | 0.78 | TRPM8 (0.67) | MEN1USP2KMT2ATRPM8TP53 | |
| SCHEMBL2718968 | 0.78 | TRPM8 (0.67) | MEN1USP2KMT2ATRPM8TP53 | |
| SCHEMBL934534 | 0.78 | PTGDR2 (0.52) | MEN1KMT2APTGDR2KCNN4KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | MEN1 2816/4885USP2 3076/4885KMT2A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.